U.S. Patent No. 8,568,761 is based on one of multiple pending U.S. Applications with claims directed toward ECM® bioscaffolds that are augmented with a variety of bioactive components, such as TGF-2, TGF-ß and DNA.
“Capturing and directing stem cell function for truly regenerating tissues requires the appropriate microenvironment, not just stem cells,” said
“The issuance of U.S. Patent No. 8,568,761 is a significant milestone in our patent prosecution efforts,” said
In addition to the Extracellular Matrix platform of devices already on the market in both the US and
Background of Extracellular Matrix (ECM) Biomaterial
The decellularized matrix material serves as a bioscaffold to allow vascular ingrowth from adjacent tissues to deliver progenitor cells and nutrients to the matrix, which then differentiate into tissue-specific cells and structures. The ECM material is gradually replaced as the patient’s own cells reinforces and rebuilds the diseased or damaged site. During repair, the matrix is naturally degraded and resorbed, leaving remodeled functional tissue where damaged or injured tissue would normally be expected. The safety of extracellular matrices has been well established in a number of different clinical applications and more than 500 published papers. Since 1999, an estimated two million patients worldwide have received an extracellular matrix implant.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the anticipated approval of pending and future patent applications related to CorMatrix® ECM® Technology, the Company's future patent application filings and the protection of the Company's intellectual property provided by any patents that issue. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that pending and future patent applications related to CorMatrix® ECM® Technology may not result in issued patent, that the issuance of any patents may be delayed, that the allowed claims, if any, may not be in line with the Company's expectations, that the Company may not be successful in enforcing its patents, and the risk factors detailed from time to time in the Company's periodic
For CorMatrix® Cardiovascular
Cookerly Public Relations
Source: CorMatrix Cardiovascular